242 related articles for article (PubMed ID: 36211558)
1. Cardiovascular disease and chimeric antigen receptor cellular therapy.
Rao A; Stewart A; Eljalby M; Ramakrishnan P; Anderson LD; Awan FT; Chandra A; Vallabhaneni S; Zhang K; Zaha VG
Front Cardiovasc Med; 2022; 9():932347. PubMed ID: 36211558
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular Complications of Chimeric Antigen Receptor T-Cell Therapy: The Cytokine Release Syndrome and Associated Arrhythmias.
Simbaqueba CC; Aponte MP; Kim P; Deswal A; Palaskas NL; Iliescu C; Jahangir E; Yang EH; Steiner RE; Lopez-Mattei J
J Immunother Precis Oncol; 2020 Aug; 3(3):113-120. PubMed ID: 35663258
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T).
Alvi RM; Frigault MJ; Fradley MG; Jain MD; Mahmood SS; Awadalla M; Lee DH; Zlotoff DA; Zhang L; Drobni ZD; Hassan MZO; Bassily E; Rhea I; Ismail-Khan R; Mulligan CP; Banerji D; Lazaryan A; Shah BD; Rokicki A; Raje N; Chavez JC; Abramson J; Locke FL; Neilan TG
J Am Coll Cardiol; 2019 Dec; 74(25):3099-3108. PubMed ID: 31856966
[TBL] [Abstract][Full Text] [Related]
4. Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies.
Totzeck M; Michel L; Lin Y; Herrmann J; Rassaf T
Eur Heart J; 2022 May; 43(20):1928-1940. PubMed ID: 35257157
[TBL] [Abstract][Full Text] [Related]
5. Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies.
Shalabi H; Sachdev V; Kulshreshtha A; Cohen JW; Yates B; Rosing DR; Sidenko S; Delbrook C; Mackall C; Wiley B; Lee DW; Shah NN
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32883871
[TBL] [Abstract][Full Text] [Related]
6. CAR T Cell Therapy-Related Cardiovascular Outcomes and Management: Systemic Disease or Direct Cardiotoxicity?
Ghosh AK; Chen DH; Guha A; Mackenzie S; Walker JM; Roddie C
JACC CardioOncol; 2020 Mar; 2(1):97-109. PubMed ID: 34396213
[TBL] [Abstract][Full Text] [Related]
7. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.
Acharya UH; Dhawale T; Yun S; Jacobson CA; Chavez JC; Ramos JD; Appelbaum J; Maloney DG
Expert Rev Hematol; 2019 Mar; 12(3):195-205. PubMed ID: 30793644
[TBL] [Abstract][Full Text] [Related]
8. T-cell Immunotherapy and Cardiovascular Disease: Chimeric Antigen Receptor T-cell and Bispecific T-cell Engager Therapies.
Stein-Merlob AF; Ganatra S; Yang EH
Heart Fail Clin; 2022 Jul; 18(3):443-454. PubMed ID: 35718418
[TBL] [Abstract][Full Text] [Related]
9. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy.
Schubert ML; Schmitt M; Wang L; Ramos CA; Jordan K; Müller-Tidow C; Dreger P
Ann Oncol; 2021 Jan; 32(1):34-48. PubMed ID: 33098993
[TBL] [Abstract][Full Text] [Related]
10. Toci or not toci: innovations in the diagnosis, prevention, and early management of cytokine release syndrome.
Banerjee R; Fakhri B; Shah N
Leuk Lymphoma; 2021 Nov; 62(11):2600-2611. PubMed ID: 34151714
[TBL] [Abstract][Full Text] [Related]
11. Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma.
Banerjee R; Marsal J; Huang CY; Lo M; Kambhampati S; Kennedy VE; Arora S; Wolf JL; Martin TG; Wong SW; Shah N
Transplant Cell Ther; 2021 Jun; 27(6):477.e1-477.e7. PubMed ID: 33831353
[TBL] [Abstract][Full Text] [Related]
12. A Computational Model of Cytokine Release Syndrome during CAR T-cell Therapy.
Zhang Z; Liu L; Ma C; Chen W
Adv Ther (Weinh); 2022 Oct; 5(10):. PubMed ID: 36590643
[TBL] [Abstract][Full Text] [Related]
13. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.
Hay KA; Hanafi LA; Li D; Gust J; Liles WC; Wurfel MM; López JA; Chen J; Chung D; Harju-Baker S; Cherian S; Chen X; Riddell SR; Maloney DG; Turtle CJ
Blood; 2017 Nov; 130(21):2295-2306. PubMed ID: 28924019
[TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor-T cell therapy-related cardiotoxicity in adults and children cancer patients: A clinical appraisal.
Camilli M; Maggio L; Tinti L; Lamendola P; Lanza GA; Crea F; Lombardo A
Front Cardiovasc Med; 2023; 10():1090103. PubMed ID: 36895831
[TBL] [Abstract][Full Text] [Related]
15. Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.
Yan Z; Zhang H; Cao J; Zhang C; Liu H; Huang H; Cheng H; Qiao J; Wang Y; Wang Y; Gao L; Shi M; Sang W; Zhu F; Li D; Sun H; Wu Q; Qi Y; Li H; Wang X; Li Z; Liu H; Zheng J; Qian W; Zhang X; Xu K
Front Immunol; 2021; 12():611366. PubMed ID: 33708205
[TBL] [Abstract][Full Text] [Related]
16. Glycyrrhizin for treatment of CRS caused by CAR T-cell therapy: A pharmacological perspective.
Qi X; Li J; Luo P
Front Pharmacol; 2023; 14():1134174. PubMed ID: 36923358
[TBL] [Abstract][Full Text] [Related]
17. Cardiotoxicity of T-Cell Antineoplastic Therapies:
Ganatra S; Dani SS; Yang EH; Zaha VG; Nohria A
JACC CardioOncol; 2022 Dec; 4(5):616-623. PubMed ID: 36636447
[TBL] [Abstract][Full Text] [Related]
18. Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T-cell Therapy: A Retrospective Study Analyzing Risks, Outcomes, and Healthcare Burden.
Patel R; Patel M; Laxmidhar F; Lakhatariya K; Patel D; Patel Z; Shaikh S
Cureus; 2023 Nov; 15(11):e49452. PubMed ID: 38152777
[TBL] [Abstract][Full Text] [Related]
19. Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy.
Smith DA; Kikano E; Tirumani SH; de Lima M; Caimi P; Ramaiya NH
Radiology; 2022 Feb; 302(2):438-445. PubMed ID: 34751616
[TBL] [Abstract][Full Text] [Related]
20. Is Prophylaxis the Only Way Out for Cytokine Release Syndrome Associated With Chimeric Antigen T-cell Therapy?
Dave P; Pallares Vela E; Cancarevic I
Cureus; 2021 Sep; 13(9):e17709. PubMed ID: 34650883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
